GlassScriptPhysician profile
Kris Mcgrath
NPI 1174563811
$492,107.34
in general payments reported to CMS, 2019-2025
24 companies · $81K in 2025
The $81K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83K · 2020: $26K · 2021: $66K · 2022: $77K · 2023: $65K · 2024: $94K · 2025: $81K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $213K · Food and Beverage: $13K · Travel and Lodging: $8,733 · Consulting Fee: $5,200 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $213,084.20 |
| Food and Beverage | $12,831.10 |
| Travel and Lodging | $8,733.19 |
| Consulting Fee | $5,200.00 |
| Education | $104.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $219,522.57 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $105,916.75 | 2019-2025 | Dupixent |
| Glaxosmithkline, LLC. | $66,954.41 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $34,991.90 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32,995.19 | 2019-2022 | |
| Amgen INC. | $18,951.51 | 2021-2025 | Tezspire |
| Pfizer INC. | $8,289.66 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,286.80 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $658.83 | 2021-2024 | Orladeyo |
| Alk-Abello, INC | $508.26 | 2020-2022 | |
| Csl Behring | $467.26 | 2023-2025 | Hizentra, Andembry, Haegarda |
| Galderma Laboratories, L.P. | $297.48 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $244.89 | 2021-2024 | Hyqvia, Cuvitru, Takhzyro |
| Hospira, INC. | $241.45 | 2023-2025 | |
| Genentech USA, INC. | $194.90 | 2019-2025 | Xolair |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $125.36 | 2019-2022 | |
| Leo Pharma INC. | $116.16 | 2022-2024 | Adbry |
| Sanofi-Aventis U.S. LLC | $96.50 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $54.82 | 2025 | Dupixent |
| Grifols USA, LLC | $47.95 | 2023-2024 | Gamunex-C, Xembify |
| Hikma Pharmaceuticals USA | $47.40 | 2024-2025 | Ryaltris |
| Kedrion Biopharma, INC. | $36.66 | 2025 | Rhogam Ultra-Filtered Plus, Koate, Gammaked |
| Biocryst Pharmaceuticals, INC. | $31.42 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $29.21 | 2025 | Neffy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kris Mcgrath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.